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S U M M A R Y
The quest for a vaccine that could have a major impact in reducing the current global burden of TB
disease in humans continues to be extremely challenging. Signiﬁcant gaps in our knowledge and
understanding of the pathogenesis and immunology of tuberculosis continue to undermine efforts to
break new ground, and traditional approaches to vaccine development have thus far met with limited
success. Existing and novel candidate vaccines are being assessed in the context of their ability to impact
the various stages that culminate in disease transmission and an increase in the global burden of disease.
Innovative methods of vaccine administration and delivery have provided a fresh stimulus to the search
for the elusive vaccine. Here we discuss the current status of preclinical vaccine development, providing
insights into alternative approaches to vaccine delivery and promising candidate vaccines. The state of
the art of clinical development also is reviewed.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Despite a 45% reduction in the mortality rate and a 41%
reduction in the prevalence rate between 1990 and 2013,
tuberculosis remains the second highest cause of death from
an infectious disease worldwide. The World Health Organization
estimates that in 2013 the global incidence of TB disease
was 9 million, with 1.5 million deaths, of which 360,000 were
associated with Human Immunodeﬁciency Virus (HIV) disease.1
With over a third of the world’s population infected with the
tubercle bacillus, and an increasing incidence of multi- and
extensively drug resistant TB, the sense of urgency to develop a
vaccine that could prevent disease transmission remains acute.
The Mycobacterium bovis bacillus Calmette-Gue´rin (BCG) vaccine
currently being used to prevent TB in infants, despite demonstrat-
ed efﬁcacy in reducing the incidence of disseminated and more
severe forms of TB, has shown limited effectiveness in prevention
of active disease, particularly in older children, adolescents and
adults.2 Mathematical modelling using an age-structured trans-* Corresponding author. Aeras, 1405 Research Boulevard, Rockville, MD 20850,
USA. Tel.: +1 301-547-2900; fax: +1 301-547-2901.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).mission model has recently demonstrated that a vaccine given to
adolescents and adults in low- and middle-income countries could
have a much larger impact on the burden of TB worldwide and is
more likely to be cost-effective than one given only to infants,
even if the vaccine has relatively low efﬁcacy and short duration
or carries a higher price.3 A major obstacle to more timely
development of an effective vaccine for tuberculosis is the absence
of any known correlates of protection. The lack of viable surrogate
biomarkers for use in clinical trials of candidate vaccines calls for
further research to explore patterns of immune responses
associated with latent infection, active disease, and disease
recurrence. In this review, the current state-of-the art of preclinical
and clinical tuberculosis vaccine development will be reviewed.
2. Preclinical development
2.1. Virus-vectored vaccines
2.1.1. Chimpanzee adenovirus (ChAd) vectors in TB vaccine
development
Replication-defective chimpanzee adenovirus vectors are
emerging as a promising new class of genetic vaccine carriers.
Adenovirus vectors are a strong choice for tuberculosis (TB)
vaccine delivery since they are natural respiratory viruses and
can target the lung where Mycobacterium tuberculosis (MTB)ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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time, have an intrinsic adjuvant effect and an acceptable safety
margin. Adenoviruses can also elicit both strong humoral and cell
mediated responses. However, clinical use of human adenoviruses
as a vaccine platform has been limited by the fact that most of the
population presents pre-existing immunity and this limits the
efﬁcacy of this virus-vectored vaccine. Termination of the
adenovirus type 5 (Ad5) HIV-1 vaccine clinical trial (STEP trial)
in 2007, due to a lack of demonstrable positive impact on virus
acquisition or virus load following infection, and the observed
increased rate of HIV infection in vaccine recipients who had prior
immunity to Ad5 and/or were circumcised, led to a decline in
enthusiasm for Ad5-vectored vaccine development. ChAds have
emerged as an alternative since humans present none or low levels
of neutralizing antibodies. Although from a different species,
ChAds can infect humans with a respiratory tract tropism. ChAd
vectors have now reached the clinical development stage and have
been shown to be capable of inducing immune responses against
encoded antigens, with added advantages of a good safety proﬁle
and ease of large-scale manufacturing.4 Further preclinical
development of a replication-deﬁcient chimpanzee adenovirus-
vectored TB vaccine is currently in progress, including a Phase
1 trial to evaluate the safety and immunogenicity of a ChAd-Ag85A
(ChAdOx1 85A) priming vaccine with and without an MVA85A
boost in healthy adults (http://clinicaltrials.gov/ct2/show/
NCT01829490).
2.1.2. Mucosal delivery of virus-vectored vaccines
BCG vaccination has been classically delivered intradermally.
However, the best route of administration for a TB vaccine still
needs to be elucidated. Evidence from mouse studies using
different viral vectors with Ag85A comparing mucosal and
parenteral vaccination supports that targeting the respiratory
tract upon delivery has a beneﬁt in protection against TB.5,6
Similarly, vaccination with BCG via aerosol or intranasally also
confers greater protection than subcutaneous (s.c.) or intradermal
(i.d.) administration in mice or guinea pigs.7–9 Published data
suggest that vaccination via the respiratory tract triggers and
sustains resident effector cells in the lung that may control the
infection. Mucosal delivery by aerosol administration has been
tested in non-human primates; aerosolized MVA-Ag85 given as a
boost to BCG primed rhesus macaques has been shown to elicit a
strong polyfunctional CD4+ T cell response in the lung measured
by PPD stimulation in BAL.10 The CD8+ response in the same
context was weak, which suggests that a heterologous boost with a
different delivery platform would be needed to complement the
MVA vaccination. This is the ﬁrst study to show a recombinant
MVA-vectored vaccine to be highly immunogenic when delivered
by the aerosol route to nonhuman primates. The results also
provided important safety and proof-of-concept data for further
evaluation of the aerosol route of immunization for use in human
clinical trials. Evaluation of an aerosolized preclinical candidate
Aeras402 (Crucell Ad35/Aeras 402-Ag85A/Ag85B/10.4) in rhesus
macaques has shown strong immunogenicity.11,12 In these
experiments, in the BAL ﬂuid the antigen speciﬁc cytokine-
producing memory T cell CD4+ subset reached 3-12% while the
CD8+ subset reached 20-50%. Both responses were sustained for
10 weeks. In the ﬁrst immunogenicity experiment the aerosol
route of administration was compared to intramuscular (i.m.)
delivery clearly showing that the parenteral vaccination could not
elicit effector T cells in the BAL ﬂuid. However despite such notable
immune responses being observed in the lungs, this was not
reﬂected in reduced bacterial load, nor in increased survival overall
upon MTB challenge. It is important to note that rhesus macaques
are highly susceptible to MTB infection and even BCG is not
efﬁciently protective.13 In this experiment an unusually high doseof MTB Erdman (275 CFUs) was used and yet the control groups did
not behave as expected (naı¨ve group did not exhibit high mortality
and BCG failed to protect when compared to naı¨ve group). Further
repeat of this experiment is needed to draw a clear conclusion and
understand whether the choice of vector or antigens is related to
the lack of biological activity observed. Aeras, in collaboration with
the National Institutes of Health Vaccine Research Center (NIH-
VRC, Bethesda, MD) and the University of Pittsburgh (Pittsburgh,
PA), are currently evaluating Ad5 constructs with antigen cassettes
that include MTb39a/MTb32a or ESAT6/Ag85B. These vaccines
have yielded strong immunogenicity in preliminary experiments
in non-human primates (Dr. Robert Seder and Dr. JoAnne Flynn,
personal communication).
The use of dry powder formulations could offer practical
advantages over needle delivery in the ﬁeld, easing compliance and
simplifying the technical operations of single use devices, storage,
and potentially eliminating a cold chain requirement. Aerosol
vaccination has been tested in measles and the results have been
encouraging, however immunogenicity and protection has been
quite heterogeneous when compared with s.c. delivery and was
also dependent on the subject age.14,15 Due to the differences in
pathogenesis and the mechanism of protection, the aerosolization
of a TB vaccine needs to be rigorously investigated and remains an
attractive strategy.
2.1.3. Cytomegalovirus as a TB vaccine vector
Rhesus cytomegalovirus (RhCMV) vectors expressing SIV
antigen have been shown to control the infection of highly
pathogenic SIVMAC239 in rhesus macaques.16 Vaccine protection
can be partly attributed to the establishment of persistence of such
vectors in the macaques and continual high expression of antigens.
Furthermore, the discovery that CMV can elicit high levels of
prolonged non-conventional CD8+ T cells that recognize unusual,
diverse and highly promiscuous epitopes and also elicit CD4+
responses17,18 makes it a very attractive platform for a TB vaccine.
Currently Aeras, in collaboration with Oregon Health & Science
University (Portland, OR), are investigating the feasibility of this
platform in non-human primates using several RhCMV vectors
expressing the MTB antigens Ag85A/85B, ESAT6, Rv3407, Rv1733c,
Rv2626c and RPF A/C/D with very encouraging preliminary results
in terms of immunogenicity and protection (Dr. Louis J Picker,
personal communication).
2.2. Electroporated DNA vaccination: a promising new technique
for TB
Recent advances in DNA vaccine delivery techniques have
renewed interest in developing a safe and effective DNA vaccine
for TB. Animal studies in mice using conventional delivery
techniques have previously shown promising results, however
immunogenicity has been modest at best.19,20Despite this, animal
studies have clearly demonstrated the induction of both CD4+ and
CD8+ T-cell responses directed against mycobacterial anti-
gens.21,22 Numerous mycobacterial antigens (including Ag85A,
Ag85B, MPT64, ESAT-6, PE/PPEs, Rv2031c, and Rv3846) have
been tested in candidate vaccines in mice and guinea pig with
mixed efﬁcacy results.23–26 More recently, the technique of
electroporation (EP) has been used as a method of enhancing the
delivery of DNA vaccines in animal models of a wide variety of
infectious diseases, including TB, with dose sparing in the range of
1000-fold compared to the administration of naked plasmid
DNA.27 Potential beneﬁts of such an approach also include a
broad-based immune response, both cellular and humoral,28
reduced rates of vaccine-induced side effects such as headache,
fever, and transient pain.29 In addition, DNA vaccines can be
readily manufactured on a large scale.30
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cellular and humoral immune responses induced by DNA vaccines
in animals and humans.28,31–34 More recently, EP DNA-based
therapeutic vaccines for a variety of cancers, directed against
human Telomerase Reverse Transcriptase (hTERT), which is highly
expressed in over 85% of human cancers, have shown promising
results in preclinical studies35 (Yan J et al., 2013). DNA Vaccine
delivery to humans using EP has been demonstrated to generate
robust TH1 and cytotoxic cellular immune responses against
human papilloma virus (HPV) serotypes 16 and 18, with the
vaccine being well tolerated, with reports of only mild injection
site reactions and no study-related serious adverse events or grade
3 and 4 adverse events.28 The use of genetically-engineered
molecular (cytokine) adjuvants, notably Interleukin-12, co-deliv-
ered with synthetic DNA vaccines has been shown to further
enhance vaccine potency.36–38 Furthermore, combination of EP
DNA vaccination with IL-12 as a genetic adjuvant has shown
enhancement of cellular immune responses to an HIV-1 DNA
vaccine.39 Experiments in NHP models with TB antigens remain to
be tested.
2.3. Heparin-binding haemaglutinin
Heparin-binding haemaglutinin (HBHA) is a protein antigen
involved in extrapulmonary dissemination of MTB, and is associated
with strong T cell responses in individuals with LTBI, but not in those
with active TB.40 A decrease in T cell responses to HBHA has been
shown to be associated with a risk of progression to active TB
disease.40,41 A recent study in a mouse challenge model of TB, using
an antigen85B-HBHA fusion protein administered in a nanoparticle
formulation intranasally as a booster after a subcutaneous BCG
vaccine prime, showed a signiﬁcant reduction in bacterial load in the
lungs compared with control mice immunized with BCG alone.42
Aeras, in collaboration with Institut Pasteur, Lille, France, is
conducting further preclinical studies of HBHA as a potential new
candidate vaccine for future use in humans.
2.4. The value of Experimental Medicine Studies
Current preclinical assessment of vaccines uses a range of animal
testing paradigms, all of which have limitations and so far have not
been shown to be predictive of clinical success. It is felt that non-
human primates (NHP) have similar immunology and TB pathogen-
esis, however limitations of availability to properly power studies
and the high cost make it difﬁcult to use for high throughput
screening. Experimental medicine studies where closely coordinat-
ed studies in both human and NHP are undertaken may provide an
alternative to the ﬁeld by testing speciﬁc hypotheses in humans with
matched immunological data in NHP, followed by subsequent
challenge studies in the NHP cohort to demonstrate functional
immunity. Such studies may be quite costly since they must be
preceded by Good Manufacturing Practice (GMP) manufacturing
and preclinical toxicology of the vaccine to be tested in man, along
with a process for selecting a suitable candidate for such studies.
Nevertheless, the beneﬁt of gaining critical knowledge from a
human trial can save time and cost in the long term, and also increase
the chances of success at later stages.
3. Clinical Development
3.1. The current repertoire of TB vaccine candidates in clinical stage
development
At least 14 candidate TB vaccines have undergone or are
currently in various phases of clinical development. They fall in to
three broad categories:1. Prime: Replacement of the existing BCG vaccine with either live
recombinant BCG (rBCG) or recombinant attenuated MTB with
demonstrated improvement in safety and protective efﬁcacy.
2. Prime-boost: Administration as a booster in recently- or
remotely-BCG primed individuals or as a booster after previous
administration of a non-BCG MTB candidate vaccine, e.g. viral-
vectored vaccines, adjuvanted subunit vaccines, and heat-
inactivated whole cell vaccines.
3. Immunotherapy: Therapeutic vaccines used as an adjunct to
chemotherapy to reduce the duration of effective treatment for
active TB disease or latent tuberculosis infection (LTBI). These
include whole-cell derived and fragmented mycobacteria.
Table 1 provides an overview of these candidate vaccines.
3.1.1. Adjuvanted subunit booster vaccines
3.1.1.1. Hybrid 1-IC31 and Hybrid 1-CAF01. Hybrid 1-IC31 (Statens
Serum Institut) is a subunit vaccine that consists of a recombinant
fusion protein of Antigen 85B (Ag85B) with Early Secretory
Antigenic Target 6 (ESAT-6), adjuvanted with IC31, an adjuvant
system that combines the immunostimulatory effects of an 11-mer
antibacterial peptide (KLKL(5)KLK) and a synthetic oligodeoxynu-
cleotide (ODN1a), which is a Toll-like receptor 9 agonist.43,44
Hybrid 1-IC31 has demonstrated safety and tolerability in healthy
adults, and immunogenicity in both non-BCG and remotely BCG-
vaccinated individuals, and in individuals with previous TB
infection. Although weakly immunogenic against ESAT-6, fusion
of this protein with Ag85B signiﬁcantly enhances immunogenicity.
The vaccine elicits a robust CD4 T-cell response as measured by
IFN-g production.44–46 Hybrid 1-CAF01 (Statens Serum Institut) is
a subunit vaccine that consists of the same recombinant fusion
protein of Ag85B and ESAT-6 as Hybrid 1-IC31, paired with a two-
component CAF01 liposomal adjuvant system. Vaccination with
Hybrid 1-CAF01 resulted in long lasting T-cell immunity charac-
terized by mainly IL-2 and TNF-producing T-cells, and the vaccine
was found to be safe and well-tolerated in humans.47 In a phase I
clinical study of the vaccine in healthy non-BCG vaccinated adults,
vaccination with Hybrid 1-CAF01 resulted in statistically signiﬁ-
cant Ag85B-speciﬁc CD4 polyfunctional CD154+ T cells compared
to H1 alone, however ESAT-6 stimulation resulted in detection of
CD4 polyfunctional CD154+ T cells responses that were not
elevated to a statistically signiﬁcant extent compared to H1 alone.
In the same study, Hybrid 1-CAF01 also demonstrated persistence
of an antigen-speciﬁc cellular immune response up to 3 years after
vaccination.48 Clinical development of Hybrid 1-IC31 and Hybrid
1-CAF01 has been sponsored by Statens Serum Institut.
3.1.1.2. H4:IC31. H4-IC31 (Sanoﬁ Pasteur) is a fusion protein of
MTB antigens 85B and TB10.4, combined with adjuvant IC31. In a
mouse model of TB, it was shown to be highly immunogenic and
induced strong protection against TB disease.49 In studies in guinea
pigs and mice, it was also shown to be safe, and demonstrated
protective efﬁcacy against pulmonary TB when administered as
priming or booster vaccine.50,51 In BCG-primed mice, it induced
expression of IFN-g, TNF-a and IL-2 triple positive CD4+ T-cells
that appeared to be correlated with protection against TB
disease.51 H4-IC31 has completed several phase I studies in adults,
including a safety and immunogenicity study of BCG vaccine and
H4-IC31 administered as a prime-boost regimen to HIV-negative,
MTB-negative, BCG-naı¨ve adults.52 A phase I/IIa safety and
immunogenicity study in BCG-primed infants (ClinicalTrials.gov
Identiﬁer: NCT01861730), and a Phase II Prevention of Infection
study in healthy adolescents (ClinicalTrials.gov Identiﬁer:
NCT02075203) are currently in progress in South Africa. Clinical
development is being co-sponsored by Sanoﬁ Pasteur and Aeras.
Table 1
Candidate tuberculosis vaccines in clinical stage development
Name Type Vaccine composition and functional attributes Strategy Study phase
Hybrid1-IC31 Adjuvanted subunit A recombinant fusion protein Ag85B and ESAT-6
adjuvanted with IC31
Prime-Boost I
Hybrid1-CAF01 Adjuvanted subunit A recombinant fusion protein of Ag85B and ESAT-6 adjuvanted with
a two-component CAF01 liposomal adjuvant system
Prime-Boost I
M72 +AS01E Adjuvanted subunit An immunogenic fusion protein (M72) derived from two MTB
antigens (Mtb32A and Mtb39A) and the adjuvant AS01E. Mtb32 is a
putative 32-kDa serine protease found in culture supernatants and
lysates of MTB. Mtb39a is a 39-kDa membrane-associated protein
with a putative role in MTB evasion
Prime-Boost IIb
H4: IC31 Adjuvanted subunit A fusion protein of MTB antigens 85B and TB10.4, combined with
adjuvant IC31
Prime-Boost II
H56: IC31 Adjuvanted subunit A fusion protein of three MTB antigens (85B, ESAT-6 and Rv2660c)
formulated in the adjuvant IC31
Prime-Boost II
ID93 + GLA-SE Adjuvanted subunit A recombinant fusion-protein of four MTB antigens (virulence-
associated Rv2608, Rv3619, Rv3620, and latency-associated
Rv1813). GLA-SE adjuvant is a Toll-like receptor 4 agonist
formulated in a squalene-based oil-in-water emulsion
Prime-Boost I
MVA85A Viral vectored Attenuated Vaccinia virus MVA vector combined with MTB antigen
85A
Prime-Boost IIb
Crucell Ad35/Aeras 402 Viral vectored A replication-deﬁcient adenovirus (Ad35) vector containing the
MTB antigens 85A, 85B and TB10.4
Prime-Boost IIb
AdAg85A Viral vectored A replication-deﬁcient serotype 5 Adenovirus vector expressing
MTB antigen 85A
Prime-Boost I
DAR 901 Whole cell Heat-inactivated whole cell Mycobacterium obuense Prime-Boost I
VPM 1002
(rBCGDureC:HLY)
Recombinant A recombinant BCG mutant expressing listeriolysin O. Perforation
of the phagosomal membrane allows egress of recombinant BCG
antigens into the cytosol, facilitating MHC**-mediated CD 8 T-cell
priming
Prime II
MTBVAC Recombinant A recombinant MTB mutant lacking expression of genes for several
virulence factors, including ESAT6, as well as mutations in genes
required for synthesis of bacterial cell wall components that protect
MTB from host defenses
Prime I
M.vaccae Whole cell Heat-inactivated whole cell vaccine Immunotherapy# III (completed)
RUTI1 Fragmented MTB Detoxiﬁed liposomal fragments of MTB Immunotherapy# II
*NA. Non-adjuvanted. **MHC. Major Histocompatibility Complex. #Adjunctive to standard anti-TB chemotherapy.
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is a recombinant fusion-protein of four MTB antigens (virulence-
associated Rv2608, Rv3619, Rv3620, and latency-associated
Rv1813). It is combined with GLA-SE, which is a glucopyranosyl
lipid adjuvant-stable squalene-based oil-in-water emulsion, which
acts as a Toll-like receptor 4. ID93+GLA-SE was shown to induce a
signiﬁcant TH1 immune response, with the generation of multifunc-
tional IFN-g, TNF-a and IL-2 CD4+ T-cells in both BCG-vaccinated
and non-BCG-vaccinated mice and guinea pigs53,54 with demon-
strated tolerability and protective efﬁcacy against TB. ID93+GLA-SE
was also shown to be protective against MDR-TB in animal models.53
In a heterologous prime-boost regimen, ID93+GLA-SE was demon-
strated to induce robust immune responses.55 ID94+GLA-SE was
shown to decrease recurrence of TB following drug treatment in
mice, and long-lived vaccine protection was observed both with a
homologous ID93+GLA-SE prime/boost regimen, or when Ad5-ID93
was given as the boost following an ID93+GLA-SE prime.55
ID93+GLA-SE is currently undergoing phase 1 clinical trials to
evaluate its safety, tolerability, and immunogenicity in healthy
adults. Clinical development is being co-sponsored by the Infectious
Diseases Research Institute and Aeras.
3.1.1.4. H56:IC31. H56:IC31 (Statens Serum Institut) is a fusion
protein of three MTB antigens (85B, ESAT-6 and the latency-
associated antigen Rv2660c) formulated in the adjuvant IC31.56 It
has been shown to be safe and immunogenic in BCG-vaccinated non-
human primate models. Furthermore, anti-TNF antibody treatment
in vaccinated non-human primates did not induce reactivation of
latent TB. The vaccine was also shown to promote a T cell response
against all three antigens characterized by a high proportion of
polyfunctional CD4+ T cells. In three different pre-exposure mousemodels, the vaccine was also demonstrated to confer protective
immunity characterized by a more efﬁcient containment of late-
stage infection than the Ag85B-ESAT6 vaccine (Hybrid 1) and BCG
vaccine. In two mouse models of latent tuberculosis, vaccination
with H56:IC31 was able to control reactivation and signiﬁcantly
lower the bacterial load compared to adjuvant control mice.56 A
Phase I, open-label, dose-escalation study in HIV negative subjects
with and without latent TB infection has been completed
(ClinicalTrials.gov Identiﬁer: NCT01967134). A phase I/IIa trial of
the safety and immunogenicity of H56:IC31 in HIV-negative, BCG
vaccinated subjects with or without latent TB is currently in progress
(ClinicalTrials.gov Identiﬁer: NCT01865487). Clinical development
is being sponsored by Statens Serum Institute and Aeras.
3.1.1.5. M72+AS01E. M72+AS01E (GlaxoSmithKline) is an immu-
nogenic fusion protein (M72) derived from two MTB antigens
(Mtb32A and Mtb39A) and the adjuvant AS01E. Mtb32 is a putative
32-kDa serine protease found in culture supernatants and lysates
of MTB. Mtb39a is a 39-kDa membrane-associated protein with a
putative role in MTB evasion. AS01E is an adjuvant system
containing the immunostimulants MPL and Quillaja saponaria
fraction 1 (QS21) combined with liposomes. The AS02 adjuvant
system differs from AS01 system only in its content of oil-in-water
in lieu of liposomes, and also contains MPL and QS21.57 It has been
used in preclinical development of M72. In a mouse TB challenge
model, immunization with M72 protein in AS01B adjuvant elicited
strong IFN-g and antibody responses to all three components of
the fusion protein, with demonstrated protection against aerosol
challenge with a virulent strain of MTB.58 In addition, immuniza-
tion of guinea pigs with M72, delivered either as DNA or as a
recombinant antigen-based vaccine, resulted in prolonged survival
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BCG immunization58 (Skeiky YAW et al., 2004). In mouse and
guinea pig TB challenge models, M72 with AS02 adjuvant was
tested for its protective capacity as a potential adjunct BCG vaccine,
demonstrating an enhanced Th1 response to BCG in mice, although
it did not further reduce the bacterial load in the lungs after aerosol
challenge. In the more stringent guinea pig disease model, when
coadministered with BCG, the vaccine signiﬁcantly improved
survival compared to BCG alone, with some animals still alive and
healthy at >100 weeks post-aerosol challenge.59 M72 with AS02A
adjuvant was immunogenic and caused no adverse reactions,
showing protection superior to that afforded by using BCG alone in
a cynomolgus monkey model.60 Long-term survival and evidence
of reversal of disease progression in monkeys immunized with
prime-boost regimen of BCG and M72/AS02A was also observed.
M72+AS01E demonstrated an acceptable safety and reactogenicity
proﬁle, and was found to be highly immunogenic, generating
both humoral and CD4+ cellular responses in a study in healthy
adults.61 In a phase IIa trial of M72+AS01E in BCG-vaccinated,
HIV-uninfected, and MTB-infected and -uninfected adults in South
Africa, the vaccine was found to be well tolerated, inducing high
frequencies of multifunctional T cells, and boosting distinct T-cell
responses primed by natural MTB infection.62 Safety and
immunogenicity of the vaccine have also been demonstrated in
HIV-positive adults.63 A phase IIb efﬁcacy trial of M72+AS01E is
currently in progress in South Africa (ClinicalTrials.gov Identiﬁer:
NCT01755598). Clinical development is being co-sponsored by
GlaxoSmithKline and Aeras.
3.2. Viral-vectored booster vaccines
3.2.1.1. MVA85A
MVA85A (Oxford University) is a subunit viral vectored
vaccine in which a recombinant strain of Modiﬁed Vaccinia virus
Ankara serves as a delivery system for the MTB antigen 85A. It has
been shown to enhance MTB-speciﬁc immune responses induced
by prior vaccination with BCG in guinea pigs, rhesus macaques,
and cattle.64–66 Its safety has been demonstrated in several
clinical trials in healthy adults, MTB and HIV infected infants,
adolescents, and children,67–73 and tolerability is comparable to
that of BCG.74 MVA85A has been demonstrated to be capable of
inducing IFN-g-producing polyfunctional CD4+T-cells,72 includ-
ing MVA85A polyfunctional Ag85A-speciﬁc CD4+ T cells in HIV-
infected adults,75 expansion of long lasting memory cell popula-
tions,76 and IFN-g-producing CD8+ T cells.74 However, a phase IIb
safety and efﬁcacy trial of MVA85A in healthy South African
infants previously vaccinated with BCG found the vaccine did not
provide additional protection to that conferred by BCG.73 A phase
II proof-of-concept, randomized, double-blind, placebo-con-
trolled study to evaluate the safety, and immunogenicity of
MVA85A against TB disease in healthy, HIV-infected adults, has
been completed (ClinicalTrials.gov Identiﬁer: NCT01151189).
Further experimental medicine studies are being conducted
using MVA85A to explore immune hypotheses in TB. Clinical
development was co-sponsored by the Oxford Emergent TB
Consortium (OETC) and Aeras.
3.2.1.2. AdAg85a
AdAg85a (McMaster University) is composed of a replication-
deﬁcient serotype 5 adenoviral vector expressing the MTB antigen
85A, an immunodominant surface antigen of MTB. Intranasal
administration of antigen 85A showed better protection against
MTB aerosol challenge than cutaneously-administered BCG
vaccine, and enhanced protection following priming with BCG
vaccine in mouse and guinea pig models.6,77,78 Intranasal AdAg85a
was shown to induce robust mucosal CD4+ and CD8+ T-cellsresponses within the airway lumen.79 A single intranasal delivery
of AdAg85a, combined as a fusion protein with the mycobacterial
antigen TB10.4, conferred a markedly improved and sustained
level of protection in the lung against MTB challenge over that
conferred by AdAg85a alone or by conventional BCG immuniza-
tion, with similarly induced levels of protection in a mouse
model.80 In a phase 1 study of the safety and immunogenicity of
AdAg85A in both BCG-naı¨ve and previously BCG-immunized
healthy adults, intramuscular immunization with AdAg85A was
found to be safe and well tolerated. AdAg85A was also found to
much more potently boost polyfunctional CD4+and CD8+ T cell
immunity in previously BCG-vaccinated volunteers. Despite
preexisting anti-Adenovirus serotype 5 humoral immunity in
most of the subjects, there was little evidence that such preexisting
immunity signiﬁcantly dampened the potency of the vaccine.81
3.2.1.3. Crucell Ad35/Aeras 402
Crucell Ad35/Aeras 402 consists of a replication-deﬁcient
adenovirus vector containing the MTB antigens 85A, 85B and
TB10.4. The vaccine induced strong CD4+ and CD8+ T-cell responses
in a mouse model, particularly when administered intranasally.82
Studies in healthy previously BCG-vaccinated adults showed the
vaccine to have an acceptable safety proﬁle, with no reports of
vaccine-related serious adverse events. Mild to moderate local
adverse events were, however, frequent.83,84 In studies in healthy
adults, the vaccine induced potent CD4+ and CD8+ T-cell responses.
In a safety and immunogenicity study in BCG-vaccinated adults,
the vaccine was well tolerated, and no vaccine-related serious
adverse events were recorded. It induced a robust CD4+ T-cell
response dominated by cells co-expressing IFN-g, tumor necrosis
factor-alpha (TNF-a), and IL-2 (‘‘polyfunctional’’ cells). It also
induced a potent CD8+ T-cell response, characterized by cells
expressing IFN-g and/or TNF-a, which persisted for the duration of
the study.83 A large Phase II safety and immunogenicity trial of
Crucell Ad35/Aeras 402 has been completed in healthy infants in
Kenya, Mozambique, and South Africa, with results pending
(ClinicalTrials.gov Identiﬁer: NCT01198366). A Phase 1 study to
assess safety and immunogenicity of a Crucell Ad35/Aeras
402 prime followed by an MVA85A boost has also been completed,
with results pending (ClinicalTrials.gov Identiﬁer: NCT01683773).
This study was sponsored by Oxford University in collaboration
with Aeras, Crucell Holland BV, Emergent Biosolutions, and the
University of Birmingham.
3.2.2. Whole cell Booster vaccine
3.2.2.1. DAR-901. DAR-901 (Dartmouth University) is a vaccine
derived from a heat-inactivated environmental non-tuberculous
mycobacterium. It was initially evaluated as for therapeutic
vaccination in MTB sputum-positive, HIV-positive and HIV-
negative patients,85–88 however its lack of efﬁcacy in the majority
of these trials resulted in a redeﬁnition of its role to one of a
prophylactic vaccine, following the DarDar phase III efﬁcacy trial,
in which vaccine efﬁcacy of 39% of a closely related vaccine (SRL-
172) against deﬁnite (culture-conﬁrmed) tuberculosis was dem-
onstrated.89 The manufacturing production method currently used
for DAR-901 differs from that of the SRL-172 vaccine used in the
DarDar trial in terms of a new, more scalable production method
developed by Aeras that uses broth rather than agar. A phase I trial
of DAR-901, sponsored by Dartmouth University in collaboration
with Aeras, is currently in progress to conﬁrm its safety,
tolerability and immunogenicity and to compare the immune
response generated to that of BCG (ClinicalTrials.gov Identiﬁer:
NCT02063555). It is being developed as a vaccine for the
prevention of TB in HIV-negative and HIV-positive persons
previously immunized with BCG.
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3.2.3.1. VPM1002. VPM1002 (Vakzine Projekt Management
GmbH) is a recombinant BCG (rBCG) mutant expressing lister-
iolysin O, a virulence factor encoded by the hly gene of Listeria
monocytogenes. It lacks the urease C gene (BCG DureC::hly),
and contains a hygromycin resistance marker.90 Listeriolysin
O-mediated perforation of the phagosomal membrane allows
egress of recombinant BCG antigens into the cytosol, facilitating
MHC-mediated CD 8 T-cell priming. In a mouse model of TB,
VPM1002 vaccination resulted in the generation of type 17 cyto-
kine production in addition to type 1 cytokine production. The
IL-17 produced was shown to enhance recruitment of antigen-
speciﬁc T cells to the lung.91 In a phase 1 open-label, dose
escalation clinical trial healthy volunteers were randomized to
receive one intradermal dose of VPM1002 or BCG. Immunogenicity
was assessed by interferon-gamma (IFN-g) production, cellular
immune response markers by ﬂow cytometry, and serum
antibodies against mycobacterial antigens. VPM1002 was found
to be safe and immunogenic for B-cell and T-cell responses.90
A phase 2 trial, evaluating safety and immunogenicity of VPM1002
in comparison with BCG in newborn infants (ClinicalTrials.gov
Identiﬁer: NCT01479972), recently has been completed (results
pending) under sponsorship of Vakzine Projekt Management
GmbH in collaboration with Children’s Infectious Disease Research
Unit, Triclinicum, the University of Stellenbosch and HJ-CTC
George in South Africa.
3.2.3.2. MTBVAC. MTBVAC (University of Zaragoza) is a recombi-
nant MTB mutant lacking expression of genes for several virulence
factors, including ESAT6 and mutations in genes required for
synthesis of bacterial cell wall components that protect MTB from
host defenses.92 In studies conducted in mouse and guinea pig
models, MTBVAC was safe, immunogenic and protective against
TB.93 It is the ﬁrst live attenuated MTB vaccine to enter clinical
trials; a phase 1 dose-escalation study is currently in progress to
evaluate safety and immunogenicity of MTBVAC compared to BCG,
sponsored by Biofabri, S.L. in collaboration with the University of
Zaragoza, Centre Hospitalier Universitaire Vaudois, TBVI, and the
European Union (ClinicalTrials.gov Identiﬁer: NCT02013245).
3.2.4. Immunotherapeutic vaccines
3.2.4.1. RUTI1. RUTI1 (Archivel Farma S.L.) is a therapeutic
vaccine that consists of detoxiﬁed liposomal fragments of MTB.
It has demonstrated efﬁcacy in controlling LTBI in experimental
mouse and guinea-pig models of TB in conjunction with a short
course of chemotherapy.94 A phase 1 trial of RUTI1 administered
subcutaneously to BCG-naı¨ve healthy adults showed it to be safe
and well tolerated, with no reports of serious adverse events,
although dose-dependent local adverse reactions were observed.
In addition, T-cell responses of blood lymphocytes to PPD and a
number of antigen subunits were elevated, when compared with
control subjects, in recipients of the vaccine.95 A phase II study to
investigate the safety, tolerability, and immunogenicity of RUTI1
following one month of isoniazid treatment in subjects with LTBI
has recently been completed (results pending; ClinicalTrials.gov
Identiﬁer: NCT01136161). The study was sponsored by Archivel
Farma S.L. in collaboration with Parexel.
3.2.4.2. Mycobacterium vaccae. A meta-analysis of 54 studies of
Mycobacterium vaccae used as adjunctive immunotherapy to TB
chemotherapy in never-treated TB showed it to result in
improvement of both sputum conversion and X-ray appearances.96
The vaccine was well tolerated, with no reports of serious adverse
events. M. vaccae provided a 72.5% protection rate in latent TBinfection (LTBI) in Chinese children, adolescents and adults from
progressing to TB disease.97 A phase III efﬁcacy and safety trial for
prevention of TB using a six-dose intramuscular regimen in
individuals with LTBI, sponsored by Anhui Zhifei Longcom Biologic
Pharmacy Co., Ltd in collaboration with the China Centers for
Disease Control, is currently in progress (ClinicalTrials.gov
identiﬁer: NCT01979900).
4. Conclusion
Development of an efﬁcacious vaccine against human TB
remains a challenging goal, despite the wealth of candidate
vaccines currently in various stages of clinical development. New
paradigms for research and development call for increased
emphasis on experimental medicine, biomarker discovery, and
novel clinical proof of concept studies to streamline vaccine
development and maximize the probability of success in late-stage
trials. Emerging platforms and techniques for more effective
delivery offer hope in paving the way for achieving the ultimate
goal of breaking the infection-transmission-disease cycle, in an
effort to substantially reduce the global burden of disease.
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